MAP3K2-DT

Across TCGA pan-cancer cohorts, MAP3K2-DT RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of MAP3K2-DT’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where MAP3K2-DT RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MAP3K2-DT is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

KIRC, LUAD, and LIHC are the cancer types where MAP3K2-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAP3K2-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	IV	+0.773	<.001	12	view →
LUAD	Male	II,III,IV	+0.753	<.001	9	view →
LIHC	Male	All	+0.875	<.001	8	view →
STAD	All	II,III,IV	+0.636	<.001	6	view →
KIRP	All	All	+0.620	<.001	6	view →
HNSC	All	All	+0.393	.001	6	view →
BRCA	All	II,III,IV	+0.372	<.001	6	view →
KICH	All	All	−0.539	.001	5	view →
LUSC	All	All	+0.446	<.001	4	view →
BLCA	Female	All	+0.607	.029	3	view →
CHOL	Female	All	+0.876	.032	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

MAP3K2-DT–KIRC

Open the KIRC breakdown →